Increased Serum Concentration of Soluble CD30 in Patients with Graves' Disease and Hashimoto's Thyroiditis

Abstract

This study investigated serum levels of the soluble form of CD30 (sCD30), which is mainly secreted from T helper 2(Th2) cells, in autoimmune thyroid diseases. The possible relationship of sCD30 to autoantibody production was also evaluated. Serum levels of sCD30 were determined by an enzyme-linked immunosorbent assay in 71 patients with Graves' disease, 37 patients with Hashimoto's thyroiditis, and 21 normal donors. Compared with normal subjects (7.1 +/- 4.5 U/mL), sCD30 was increased in patients with Graves' disease (29.2 +/- 25.2 U/mL, P < 0.0001) and in patients with Hashimoto's thyroiditis (29.9 +/- 26.9 U/mL, P < 0.0001). In Graves' disease, sCD30 levels were higher in thyrotoxic patients (41.7 +/- 31.2 U/mL, P < 0.001) than in remission patients (15.8 +/- 11.0 U/mL), and a significant correlation was observed between sCD30 levels and serum activities of TSH receptor antibody (r = 0.444, P < 0.0001). In Hashimoto's thyroiditis, sCD30 levels were higher in patients with transient destructive thyrotoxicosis caused by the aggravation of the disease (48.8 +/- 34.4 U/mL, P < 0.05) than in euthyroid patients (24.2 +/- 19.4 U/mL). These data suggest that serum sCD30 is a valuable marker of disease activity and support an important role of the Th2-type immune response in the pathogenesis in Graves' disease and Hashimoto's thyroiditis.

CD30 Expression and Interleukin-4 and Interferon-y Production of Intrathyroidal Lymphocytes in Graves' Disease

“…Thus, it is reasonable to speculate that the disease may be dependent on Th2 predominance. Our recent results of increased serum IL-5 and soluble CD30 concentrations in Graves' disease (8,9) support this Th2 predominant hypothesis. However, reported data using the thyroid gland from Graves' disease do not always support this.…”

“…Mouse Th2 cells secrete type 2 cytokines: IL-4, (7). Recently, we reported that soluble CD30 and IL-5 were IL-5, IL-6, IL-9, IL-10, and IL-13, and promote produc-increased in Graves' disease and Hashimoto's thyroiditis, tion of antibodies, Human Thl and Th2 cells produce cy-and suggested that the type-2 immune response is importokines in a similar pattern, although the synthesis of IL-tant in the pathogenesis of autoimmune thyroid diseases 2, IL-6, IL-10, and IL-13 is not so tightly restricted to a (8,9). The high serum levels of soluble CD30 and IL-5 may single subset as in mouse T cells (2).…”

Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure

“…Patients with pathological conditions, including lymphoproliferative disorders [12,13], viral infections [14,15] or autoimmune diseases [16,17] exhibit increased serum levels of sCD30, mainly in association with advanced disease and poor prognosis [3]. The quantitation of serum CD30 in patients waiting for a kidney transplant has shown that sCD30 is an excellent pre-transplant predictor of kidney graft outcome, allowing the identification of high-risk recipients even in the absence of preformed anti-HLA antibodies [18][19][20].…”

Increase in Serum Levels of Autoantibodies after Attack of Seasonal Allergic Rhinitis in Patients with Graves’ Disease

“…In patients with Graves’ disease, peripheral eosinophil counts were significantly increased [4]. Furthermore, serum concentrations of interleukin (IL) 5 [5], soluble CD30 [6], IgE [7]and eosinophil-derived neurotoxin were increased [8]. Moreover, it has recently been clarified that the association of seasonal allergic rhinitis was frequent in Graves’ disease and rare in painless thyroiditis [9].…”